Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 27
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Acharya, Dhiraj and Bai, Fengwei 2016. West Nile Virus.


    Gowen, Brian Ennis, Jane Bailey, Kevin Vest, Zachary Scharton, Dionna Sefing, Eric and Turner, Jeffrey 2014. Single-Dose Intranasal Treatment with DEF201 (Adenovirus Vectored Consensus Interferon) Prevents Lethal Disease Due to Rift Valley Fever Virus Challenge. Viruses, Vol. 6, Issue. 3, p. 1410.


    Hauser, Goran Awad, Tahany Brok, Jesper Thorlund, Kristian Štimac, Davor Mabrouk, Mahasen Gluud, Christian Gluud, Lise Lotte and Hauser, Goran 2014. Cochrane Database of Systematic Reviews.


    Hahné, Susan JM Veldhuijzen, Irene K Wiessing, Lucas Lim, Tek-Ang Salminen, Mika and Laar, Marita van de 2013. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infectious Diseases, Vol. 13, Issue. 1,


    Hartwell, Debbie Jones, Jeremy Baxter, Louise and Shepherd, Jonathan 2012. SHORTENED PEGINTERFERON AND RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS C. International Journal of Technology Assessment in Health Care, Vol. 28, Issue. 04, p. 398.


    Jafferbhoy, H. Miller, M.H. Dunbar, J.K. Tait, J. Mcleod, S. and Dillon, J.F. 2012. Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection. Journal of Viral Hepatitis, Vol. 19, Issue. 2, p. 112.


    Cheng, Mindy M. Alfonso, Rafael Best, Jennie H. Garrison, Louis P. Bruhn, David and Veenstra, David L. 2010. The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment. Journal of Medical Economics, Vol. 13, Issue. 2, p. 193.


    Sroczynski, G. Esteban, E. Conrads-Frank, A. Schwarzer, R. Mühlberger, N. Wright, D. Zeuzem, S. and Siebert, U. 2010. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. Journal of Viral Hepatitis, Vol. 17, Issue. 1, p. 34.


    Awad, Tahany Thorlund, Kristian Hauser, Goran Mabrouk, Mahasen Stimac, Davor Gluud, Christian and Awad, Tahany 2009. Cochrane Database of Systematic Reviews.


    Awad, Tahany Thorlund, Kristian Hauser, Goran Mabrouk, Mahasen Stimac, Davor Gluud, Christian and Awad, Tahany 2009. Cochrane Database of Systematic Reviews.


    Awad, Tahany Thorlund, Kristian Hauser, Goran Mabrouk, Mahasen Stimac, Davor Gluud, Christian and Awad, Tahany 2009. Cochrane Database of Systematic Reviews.


    Awad, Tahany Thorlund, Kristian Hauser, Goran Mabrouk, Mahasen Stimac, Davor Gluud, Christian and Awad, Tahany 2009. Cochrane Database of Systematic Reviews.


    Awad, Tahany Thorlund, Kristian Hauser, Goran Mabrouk, Mahasen Stimac, Davor Gluud, Christian and Awad, Tahany 2009. Cochrane Database of Systematic Reviews.


    Awad, Tahany Brok, Jesper Thorlund, Kristian Hauser, Goran Stimac, Davor Mabrouk, Mahasen Gluud, Christian Gluud, Lise Lotte and Awad, Tahany 2009. Cochrane Database of Systematic Reviews.


    Kang, Jung Seok DeLuca, Patrick P and Lee, Kang Choon 2009. Emerging PEGylated drugs. Expert Opinion on Emerging Drugs, Vol. 14, Issue. 2, p. 363.


    Siebert, Uwe Sroczynski, Gaby Aidelsburger, Pamela Rossol, Siegbert Wasem, Jürgen Manns, Michael P. McHutchison, John G. and Wong, John B. 2009. Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response. PharmacoEconomics, Vol. 27, Issue. 4, p. 341.


    Sroczynski, G. Esteban, E. Conrads-Frank, A. Schwarzer, R. Muhlberger, N. Wright, D. Zeuzem, S. and Siebert, U. 2009. Long-term effectiveness and cost-effectiveness of screening for Hepatitis C virus infection. The European Journal of Public Health, Vol. 19, Issue. 3, p. 245.


    Chou, R. Carson, S. and Chan, B. K. S. 2008. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials. Journal of Viral Hepatitis, Vol. 15, Issue. 8, p. 551.


    De Compadri, Paola Koleva, Daniela Mangia, Alessandra Motterlini Stat Sci, Nicola and Garattini, Livio 2008. Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus. Journal of Medical Economics, Vol. 11, Issue. 1, p. 151.


    Marsh, Kevin 2008. The cost of future problem drug use associated with young people’s behaviors and circumstances. Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 8, Issue. 6, p. 539.


    ×
  • International Journal of Technology Assessment in Health Care, Volume 21, Issue 1
  • January 2005, pp. 47-54

Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: A systematic review and economic evaluation

Abstract

Objectives: To assess the clinical-effectiveness and cost-effectiveness of pegylated interferon alfa (2a and 2b) combined with ribavirin in previously untreated patients with moderate to severe chronic hepatitis C, compared with the current standard treatment, which is nonpegylated interferon alfa combined with ribavirin.

Methods: Systematic review and economic evaluation. A sensitive search strategy was applied to several electronic bibliographic databases. Relevant studies were critically appraised and meta-analyzed. A hypothetical cohort of 1,000 patients entered a Markov model and were followed up for a more than 30-year period to predict natural history, duration spent in each health state, and treatment costs.

Results: Two fully published Phase III randomized controlled trials were included. Methodological quality was generally good. Dual therapy with pegylated interferon was significantly more effective than nonpegylated dual therapy with a pooled sustained virological response rate (SVR) of 55 percent (95 percent confidence interval [CI], 52–58 percent) compared with 46 percent (95 percent CI, 43–49 percent). The pooled relative risk of remaining infected was 0.83 (95 percent CI, 0.76–0.91 percent). Genotype was the strongest predictor of outcome, with SVRs in patients with the more responsive genotypes 2 and 3 reaching up to 80 percent. The incremental cost per quality-adjusted life year (QALY) for pegylated dual therapy compared with nonpegylated dual therapy was £12,123. The cost per QALY remained under £30,000 for most patient subgroups and in sensitivity analyses.

Conclusions: Pegylated interferon is clinically effective, represents good value for the money, and is a significant advance in the treatment of this insidious disease.

Copyright
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: